2 ms·
BionTech needed a large partner for clinical trials and initial prodcution. The IP is still largely Biontech, they now have a significant production footprint a
by hef19898 5y ago
BionTech needed a large partner for clinical trials and initial prodcution. The IP is still largely Biontech, they now have a significant production footprint as well. Not to bad, plus huge global sales. And the mRNA know-how mostly stayed with Biontech. For once I don't see any lack in strategy here.
- mytailorisrich 5y agoGermany has large pharma companies and could have made sure one of them was picked in the same way the UK did. Plainly, this was a war situation with countries brought to their knees and Germany handed production of a key weapon that they had developed to a foreign entity. In such a situation IP means nothing if you don't control the factories. Compare to the UK who very clearly understood the situation and intervened. That's serious lack of sovereign strategy and assertiveness on Germany's part, but, again, I don't think they are willing to, or even can, say 'no' to the US.